Sanofi India Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3zinvhyue9ja18upnsm259gh.pdf

Key Takeaways


Partnership Transition: The Quarter's Dominant Swing Factor

Rachid Ayari: "The fact that we are not giving any forward-looking, but I think the fluctuation will continue in 2026. I think by end of 2026, we will stabilize this partnership because, as mentioned by Deepak as well, that there are certain agreements with the partners in terms of stock replenishment and this systematically will continue to give kind of fluctuation for 2026 I think."

Diabetes Franchise: Defending Share in a Shifting Market

Deepak Arora: "Soliqua has unique USPs basically controlling not only diabetes, but also... with insulin usage, there is an increase in the weight. Soliqua provides weight neutrality with better control. So that's a unique feature what Soliqua brings in with very low or no hypoglycemia."

Profitability: Margin Compression Without Segment Disclosure


Strategy & Portfolio Boundaries

Rachid Ayari: "So based on the group strategy as well so we want to focus on certain therapeutic areas and not to expand. If there is opportunity, yes. But for now, the strategy for the listed company is to focus mainly on diabetes insulin... But diversifying today to another area, we don't see that there will be a synergy with the current portfolio with the current team."

Guidance & Commitments

CommitmentSpecificsTimeline
Partnership stabilizationFluctuation will continue through 2026; stabilization expected once stock replenishment agreements normalizeBy end of 2026
Partnership growthPartnership expected to grow, but with quarter-to-quarter fluctuation persistingThrough 2026
Institutional business fixInnovative access model to tackle aggressive competition discountAs we get into 2026
Soliqua public-sector entrySoliqua entering the public sectorNew, no specific date
Toujeo public-sector expansionToujeo expansion in the public sectorNew, no specific date
Final dividendFinal dividend to be approved at general assemblyMay/June of this year
New publicationsReal-world evidence from LANDMARC and Soliqua real-world studyThis year / IDF next year

Key Metrics

MetricQ3 FY26
Revenue (domestic net sales, full year)₹1,511 cr, diabetes ~half, partnership ~half
Diabetes segment growth (Q3)11%, double-digit growth
Partnership segment growth (full year)-2% vs last year, stabilizing
Partnership sales (Q3)~₹200 cr (per an analyst's math)
Partnership sales (Q4)₹153 cr, impacted by phasing, stock replenishment, frozen periods, and gross-to-net for OADs
Operating expenses-17% YoY in the quarter and full year, reflecting partnership strategy
Profit before tax (full year)+1%, significant drop in the quarter due to phasing and top-line stock movement
Profit before exceptional items (full year)+1%
Profit after tax (full year)+4%
EBITDA margin21.5%, an 8-quarter low, impacted by phasing
ExportSignificant drop in the quarter and full year, related to Ankleshwar site divestment
Lantus market share (basal segment)31% leadership, volume acceleration of +6%
Toujeo growthDouble digits
Soliqua growthDouble digits
Overall analog market growth+6%
Partnership volume growth (excl. cert effect)+4%
IQVIA growth for Emcure portfolio (cardio and OAD)+5%
Soliqua real-world study enrollment105 patients across 9 sites in India, last patient in 12 Dec 2025